Market Cap | 536.83M | P/E | - | EPS this Y | 25.00% | Ern Qtrly Grth | - |
Income | -26.54M | Forward P/E | -28.69 | EPS next Y | -5.70% | 50D Avg Chg | -28.00% |
Sales | 8k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
Dividend | N/A | Price/Book | 184.46 | EPS next 5Y | - | 52W High Chg | -50.00% |
Recommedations | 2.00 | Quick Ratio | 5.80 | Shares Outstanding | 34.54M | 52W Low Chg | 286.00% |
Insider Own | 17.85% | ROA | -44.61% | Shares Float | 27.96M | Beta | - |
Inst Own | 20.57% | ROE | -88.57% | Shares Shorted/Prior | 1.13M/1.24M | Price | 20.66 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 46,503 | Target Price | 19.20 |
Oper. Margin | -341,437.50% | Earnings Date | - | Volume | 24,467 | Change | 0.78% |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Roth MKM | Buy | Aug 27, 24 |
HC Wainwright & Co. | Buy | Aug 15, 24 |
Benchmark | Speculative Buy | Jun 3, 24 |
Benchmark | Speculative Buy | May 31, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
Benchmark | Speculative Buy | Apr 3, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
HC Wainwright & Co. | Buy | Nov 27, 23 |
Benchmark | Speculative Buy | Nov 24, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Tyree James L | Director Director | Dec 13 | Sell | 13.32 | 9,000 | 119,880 | 3,460 | 12/14/23 |
Thomas John | Director Director | Dec 13 | Sell | 13.58 | 9,000 | 122,220 | 463,460 | 12/14/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Dec 07 | Sell | 11.8477 | 36,800 | 435,995 | 32,535 | 12/08/23 |
Szalay Aladar | 10% Owner 10% Owner | Oct 25 | Sell | 19.3965 | 5,704 | 110,638 | 1,371,545 | 10/26/23 |
Szalay Aladar | 10% Owner 10% Owner | Oct 23 | Sell | 19.9725 | 49,987 | 998,365 | 1,377,249 | 10/25/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Oct 24 | Sell | 19.11 | 5,200 | 99,372 | 106,135 | 10/25/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Oct 24 | Option | 6 | 5,200 | 31,200 | 111,335 | 10/25/23 |
Thomas John | Director Director | Oct 16 | Sell | 20.9 | 3,333 | 69,660 | 472,460 | 10/16/23 |
Szalay Aladar | 10% Owner 10% Owner | Oct 05 | Sell | 25.18 | 14,251 | 358,840 | 1,427,236 | 10/10/23 |
Szalay Aladar | 10% Owner 10% Owner | Oct 03 | Sell | 25.4885 | 75,690 | 1,929,225 | 1,441,487 | 10/04/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 27 | Sell | 24.3 | 13,546 | 329,168 | 1,517,177 | 09/29/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 25 | Sell | 25.14 | 42,263 | 1,062,492 | 1,530,723 | 09/27/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 21 | Sell | 27.84 | 16,591 | 461,893 | 1,572,986 | 09/25/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 18 | Sell | 25.19 | 62,459 | 1,573,342 | 09/20/23 | |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Sep 15 | Sell | 21.92 | 10,400 | 227,968 | 106,135 | 09/18/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Sep 15 | Option | 6 | 10,400 | 62,400 | 116,535 | 09/18/23 |
Thomas John | Director Director | Sep 15 | Sell | 23.01 | 6,667 | 153,408 | 475,793 | 09/18/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Sep 13 | Sell | 21.1385 | 29,800 | 629,927 | 106,135 | 09/15/23 |
Smither John W | Director Director | Sep 13 | Sell | 20.78 | 900 | 18,702 | 6,920 | 09/14/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 11 | Sell | 22.05 | 52,616 | 1,160,183 | 79,600 | 09/13/23 |
Szalay Aladar | 10% Owner 10% Owner | Sep 07 | Sell | 23.98 | 37,277 | 893,902 | 132,216 | 09/11/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Aug 30 | Sell | 24.70 | 19,800 | 489,060 | 135,935 | 08/30/23 |
Yu Yong | VP, Clinical Trial O.. VP, Clinical Trial Operations | Aug 18 | Sell | 23.73 | 3,265 | 77,478 | 155,735 | 08/22/23 |
Zindrick Thomas | President and CEO President and CEO | Aug 18 | Sell | 23.73 | 8,349 | 198,122 | 14,651 | 08/22/23 |